 |
Top 10 Radiopharmaceutical startups
Oct 24, 2024 | By Jason Kwon | 24 |
These startups develop drugs that contains a radioactive substance used to destroy cancer cells or other pathogenic tissues.
1
Country: USA | Funding: $331M
Aktis Oncology develops radiopharmaceutical treatments for solid tumors.
Aktis Oncology develops radiopharmaceutical treatments for solid tumors.
2
Country: Canada | Funding: $210.5M
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
3
Country: USA | Funding: $418M
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes.
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes.
4
Country: USA | Funding: $250M
Mariana Oncology designs radiopharmaceuticals to pierce solid tumors better than antibodies and deliver optimized high radiation activity doses without the side effects tied to chemotherapy and toxin-based strategies.
Mariana Oncology designs radiopharmaceuticals to pierce solid tumors better than antibodies and deliver optimized high radiation activity doses without the side effects tied to chemotherapy and toxin-based strategies.
5
Country: Canada | Funding: $148.3M
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
6
Country: USA | Funding: $135M
Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics.
Radionetics Oncology is a pharmaceutical company that focuses on the discovery and development of novel radiotherapeutics.
7
Country: USA | Funding: $90M
Convergent Therapeutics is a pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate cancers
Convergent Therapeutics is a pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate cancers
8
Country: Denmark | Funding: $52.3M
MedTrace provides 15O water for positron emission tomography (PET) imaging. The startup’s platform consists of an automated hardware system for producing, dosing, and injecting 15O water and analytical software for image processing.
MedTrace provides 15O water for positron emission tomography (PET) imaging. The startup’s platform consists of an automated hardware system for producing, dosing, and injecting 15O water and analytical software for image processing.
9
Country: UK
Theragnostics develops fluorine-18 based radiopharmaceuticals. THG-008, the startup’s lead drug, is a fluorine-18 radiolabelled poly-ADP-ribose polymerase (PARP) inhibitor (rPARPi). It aids in head and neck cancer, as well as brain cancer imaging.
Theragnostics develops fluorine-18 based radiopharmaceuticals. THG-008, the startup’s lead drug, is a fluorine-18 radiolabelled poly-ADP-ribose polymerase (PARP) inhibitor (rPARPi). It aids in head and neck cancer, as well as brain cancer imaging.
10
Country: Germany
Navigo Proteins develops novel radio-conjugates. The startup engineers Affilin, artificial proteins designed to selectively bind antigens, radio conjugates.
Navigo Proteins develops novel radio-conjugates. The startup engineers Affilin, artificial proteins designed to selectively bind antigens, radio conjugates.
